Price T Rowe Associates Inc Moon Lake Immunotherapeutics Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Price T Rowe Associates Inc holds 2,980,249 shares of MLTX stock, worth $155 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,980,249
Previous 2,561,512
16.35%
Holding current value
$155 Million
Previous $113 Million
33.41%
% of portfolio
0.02%
Previous 0.01%
Shares
10 transactions
Others Institutions Holding MLTX
# of Institutions
124Shares Held
58.2MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$1.13 Billion34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$443 Million30.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$145 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$121 Million0.02% of portfolio
-
Holocene Advisors, LP New York, NY1.59MShares$82.7 Million0.35% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.93B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...